27. August 2024
Against the tide – HTGF portfolio SciRhom company rewarded for courage with EUR 63 million Series A financing
In July, HTGF portfolio company SciRhom announced one of the largest financing rounds in German biotechnology this year and will soon begin clinical trials of its first drug. The company’s unique therapeutic approach targets a central node of the immune system. In this interview, company co-founder and current SciRhom Managing Director and COO Jens Ruhe, his Co-Managing Director and CEO Jan Poth and Frank Hensel, Principal at HTGF, provide insights into the collaboration that has been in p
10. July 2024
HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration
Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX
Dr. Linda Greenbaum joins HepaRegeniX as CMO
Tuebingen (Germany), July 10, 2024 – HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, today announced the closing of a Series C rou
9. July 2024
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases.
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy.
Munich, Germany, July 9, 2024 – SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced today the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Pa
25. March 2024
Successful exit for HTGF: Novo Nordisk to acquire Cardior Pharmaceuticals
Novo Nordisk will acquire Cardior for up to 1.025 billion Euros in upfront and potential milestone payments.
Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart.
High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors, participated in the first financing round in 2017.
Bonn, Germany, 25 March 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that N
14. March 2024
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
Financing round co-led by EQT Life Sciences and Nextech Invest [1], with participation from current and new leading global biotechnology investors
Proceeds will support clinical evaluation of lead solid tumor ADC candidates, TUB-030 and TUB-040, further technology development and expansion into the US
MUNICH, GERMANY, March 14, 2024 – Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round
15. August 2023
Investments in drug development: “We need to get to the source of the deals”
Dr. Frank Hensel is Principal at High-Tech Gründerfonds (HTGF), where he is primarily responsible for start-ups from the field of drug development. Before joining HTGF, he was a successful entrepreneur himself and is now able to share his practical experience with start-ups. We sat down for a chat with him about the challenges of the sector, how HTGF is on the lookout for new innovations and why partnerships are especially important in this field.
Frank, your investments are focused
15. May 2023
Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic
Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its pipeline of Treg candidates
Financing co-led by Fountain Healthcare Partners, Forbion and Andera Partners with support from existing investors
Bernard Coulie appointed as Independent Chairman with immediate effect
May 15, 2023, Ghent, Belgium – Dualyx NV, a Ghent based biotech developing next generation immune modulators, today announces that it has
13. April 2023
Alentis Therapeutics closes $105 million Series C funding to advance transformational medicines for Claudin-1
Proceeds will fund:
Clinical programs ALE.F02 and ALE.C04 – two first-in-class anti-Claudin-1 (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors
The platform to engineer CLDN1 antibody drug conjugates (ADC) and bispecific antibodies
Basel, Switzerland – 13 April 2023, Alentis Therapeutics (“Alentis”), the Claudin-1 (CLDN1) company, is a clinical-stage biotech company developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. Today, A
